Tessera

Folgen

Matt Alexander

@vascularimmuno.bsky.social

Physician-scientist. Cardiovascular medicine, hypertension, immunology, vascular biology. Views my own.

4 Posts167 Follower 59 Folgt

Anand Vaidya @anandvaidya17.bsky.social · 5mo ago

Re-Defining Primary Aldosteronism authors.elsevier.com/a/1mqFw2d9GI... @jaccjournals.bsky.social #JACC

Stephen P Juraschek, MD, PhD, FAHA, AHSCP-CHS @spjuraschek.bsky.social · 6mo ago

New lipid guidelines are out!!! 2026 ACC/AHA Guideline on the Management of Dyslipidemia www.ahajournals.org/doi/10.1161/...

American Heart Association Journals

ahajournals.org

John Giacona, PhD, PA-C @giaconajohn.bsky.social · 6mo ago

Excellent overview in The Washington Post on the systemic impact of sustained hypertension — from LVH to CKD and cognitive decline. Kudos to Drs. @drwanpen.bsky.social , John B, and @jordybc.bsky.social for evidence base insight. 🔗 www.washingtonpost.com/wellness/202... #Hypertension #Cardiology

What high blood pressure does to your body

Hypertension can affect your mind, heart, eyes and more, often without causing any obvious symptoms at all.

washingtonpost.com

@thecurbsiders.bsky.social · 6mo ago

🧠 Dr. Vaidya’s @anandvaidya17.bsky.social practical approach to primary aldo, distilled into one clean, clinic-ready infographic: This is high-yield, no-fluff, practice-changing stuff.

Matt Alexander @vascularimmuno.bsky.social · 7mo ago

Really interesting case!

Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · 7mo ago

a young woman with hypertension and hypokalemia, which is not PA! or FMD... www.nejm.org/doi/full/10.... in @nejm.org

Imaging Studies of the Abdomen and Pelvis.
A three-dimensional volume-rendered image of the abdominal aorta and iliac arteries (Panel A) shows no evidence of stenosis or renal-artery abnormalities. An axial CT image, obtained in the portovenous phase after the administration of intravenous contrast material (Panel B), reveals a hypoenhancing, partially exophytic mass in the left kidney (arrow). A sagittal image obtained from contrast-enhanced CT in the portovenous phase (Panel C) shows the same lesion (white arrow), with a more hypodense focus along its superior margin (black arrow). An axial T1-weighted MRI, obtained after the administration of intravenous contrast material (Panel D), shows a hypointense, hypoenhancing lesion in the left kidney (arrow). A coronal T2-weighted MRI (Panel E) shows the lesion with predominantly hypointense signal (white arrow) and a small superior cystic component (black arrow).

@thecurbsiders.bsky.social · 9mo ago

🚨 Fresh Hypertension Guidelines Alert 🚨 Don’t get caught treating high blood pressure like it’s 2024 👀  In Episode #509, West Philly doc Dr. Jordy Cohen @jordybc.bsky.social keeps our hypertension management fresh with a clear walk-through of the new HTN guidelines & more! www.thecurbsiders.com

J. Brian Byrd @jbrianbyrd.bsky.social · 9mo ago

Dan Batlle & I wrote about testing for primary aldosteronism, bringing a critical lens to the usual approach www.ahajournals.org/doi/full/10....

American Heart Association Journals

ahajournals.org

Dr Anastasia S Mihailidou PhD FAHA FCSANZ FESC @anastasiasmihaili.bsky.social · 9mo ago

⏳In 7 days an impt discussion on #BloodPressure across Womens #Lifespan coordinated by #NIH #NHLBI There is still time to register👉🏻 web.cvent.com/event/e7c2bdc3… Looking fwd to presenting & learning! Hope you will join #CardioSky #MedSky

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · 10mo ago

Ahead of #KidneyWk25, we are recruiting a hypertension fellow to the Stanford Hypertension Center for July 2026. Please come find me at ASN. med.stanford.edu/nephrology/e...

Hypertension Fellowship

med.stanford.edu

Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · 12mo ago

The new ⌚️ will have hypertensive notifications This doesn’t seem like a cuffless BP - but more like a notification ‘you may have hypertension, go check your BP’ ? From www.apple.com/newsroom/202... @jordybc.bsky.social @drwanpen.bsky.social @spjuraschek.bsky.social @daichishimbo.bsky.social?

Hypertension Notifications

Building on its suite of advanced health features, Apple Watch Series 11 introduces groundbreaking hypertension notifications, which can alert users if signs of chronic high blood pressure — or hypertension — are detected.5 Hypertension is the leading modifiable risk factor for heart attack, stroke, and kidney disease, and impacts approximately 1.3 billion adults globally. It is frequently undiagnosed because it often has no symptoms, many people do not see a doctor regularly, and even during a clinical visit, it can be easily missed with a single measurement.
Hypertension notifications on Apple Watch use data from the optical heart sensor to analyze how a user’s blood vessels respond to the beats of the heart. The algorithm works passively in the background reviewing data over 30-day periods, and will notify users if it detects consistent signs of hypertension. These notifications provide users with valuable insights into their health as it relates to this widespread condition simply by wearing their Apple Watch, so they can begin making potentially lifesaving behavioral changes, or start treatment to reduce their risk of serious, long-term health events.
Replay video: Apple Watch Series 11 Hypertension Notifications

Hypertension notifications use data from the optical heart sensor on Apple Watch to analyze how a user’s blood vessels respond to the beats of the heart.
Like all of Apple’s health features, hypertension notifications are grounded in rigorous scientific validation. The feature was developed with advanced machine learning and training data from multiple studies totaling over 100,000 participants. Its performance was then validated in a clinical study of over 2,000 participants. While hypertension notifications will not detect all instances of hypertension, with the reach of Apple Watch, the feature is expected to notify over 1 million people with undiagnosed hypertension within the first year.

Hypertension notifications use data from the optical heart sensor on Apple Watch to analyze how a user’s blood vessels respond to the beats of the heart.
Like all of Apple’s health features, hypertension notifications are grounded in rigorous scientific validation. The feature was developed with advanced machine learning and training data from multiple studies totaling over 100,000 participants. Its performance was then validated in a clinical study of over 2,000 participants. While hypertension notifications will not detect all instances of hypertension, with the reach of Apple Watch, the feature is expected to notify over 1 million people with undiagnosed hypertension within the first year.
“Hypertension is the leading preventable cause of heart attack and stroke, yet millions remain undiagnosed,” said Harlan Krumholz, MD, SM, cardiologist and scientist at Yale University and Yale New Haven Hospital. “Making accurate detection easy and part of daily life can help people get care earlier and prevent avoidable harm.”
A user’s iPhone and Apple Watch Series 11 show “Possible Hypertension” and offer more details.
Hypertension notifications were developed with advanced machine learning and training data from multiple studies totaling over 100,000 participants.
If users receive a hypertension notification, it is recommended that they log their blood pressure for seven days using a third-party blood pressure cuff and share the results with their provider at their next visit, which is consistent with the latest American Heart Association guidelines for the diagnosis and management of hypertension.
Clearance for hypertension notifications from the FDA and other regulators is expected soon, and the feature will be available in more than 150 countries and regions — including the U.S. and the EU — this month. Hypertension notifications will be available on Apple Watch Series 9 and later, and Apple Watch Ultra 2 and later, with watchOS 26.

Hypertension Notifications

Hypertension notifications use data from the optical heart sensor on Apple Watch to analyze how a user’s blood vessels respond to the beats of the heart.
Like all of Apple’s health features, hypertension notifications are grounded in rigorous scientific validation. The feature was developed with advanced machine learning and training data from multiple studies totaling over 100,000 participants. Its performance was then validated in a clinical study of over 2,000 participants. While hypertension notifications will not detect all instances of hypertension, with the reach of Apple Watch, the feature is expected to notify over 1 million people with undiagnosed hypertension within the first year.
“Hypertension is the leading preventable cause of heart attack and stroke, yet millions remain undiagnosed,” said Harlan Krumholz, MD, SM, cardiologist and scientist at Yale University and Yale New Haven Hospital. “Making accurate detection easy and part of daily life can help people get care earlier and prevent avoidable harm.”
A user’s iPhone and Apple Watch Series 11 show “Possible Hypertension” and offer more details.
Hypertension notifications were developed with advanced machine learning and training data from multiple studies totaling over 100,000 participants.
If users receive a hypertension notification, it is recommended that they log their blood pressure for seven days using a third-party blood pressure cuff and share the results with their provider at their next visit, which is consistent with the latest American Heart Association guidelines for the diagnosis and management of hypertension.
Clearance for hypertension notifications from the FDA and other regulators is expected soon, and the feature will be available in more than 150 countries and regions — including the U.S. and the EU — this month. Hypertension notifications will be available on Apple Watch Series 9 and later, and Apple Watch Ultra 2 and later, with watchOS 26.

Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · last yr.

Beta blockers remain overused for #hypertension in the VA (though the tens line is going down, very slowly) jamanetwork.com/journals/jam... in @jama.com from @jordybc.bsky.social et al OTOH: I think ESRD should count as a somewhat compelling indication? Almost all HD pts here are on bisoprolol

Figure 2. Fully Adjusted Prevalence Ratios (PRs) for Factors Associated With β-Blocker Initiation

Figure 1. Compelling Indication Status Among Veterans Who Initiated a β-Blocker for Hypertension Treatment, 2000 Through 2022

Josh Leisring @joshleisring.bsky.social · last yr.

Commentary on expanded screening for primary aldosteronism in the new HTN guideline. www.ahajournals.org/doi/10.1161/... 🔓

Stephen P Juraschek, MD, PhD, FAHA, AHSCP-CHS @spjuraschek.bsky.social · last yr.

If you want fresh, live discussion on the new guidelines, join us in Baltimore this September! Writers will present their rationales and future directions! Hypertension 2025 Scientific Sessions - Professional Heart Daily | American Heart Association share.google/WD0vuS8NuHnF...

Hypertension 2025 Scientific Sessions

Join the Hypertension Scientific Sessions to explore the latest research, treatment strategies, and advancements in hypertension management. Register now!

share.google

Stephen P Juraschek, MD, PhD, FAHA, AHSCP-CHS @spjuraschek.bsky.social · last yr.

New AHA Hypertension guidelines are out! professional.heart.org/en/science-n...

2025 High Blood Pressure Guideline

The 2025 High Blood Pressure Guideline replaces the 2017 ACC/AHA High Blood Pressure Guideline, incorporating updated recommendations based on the latest clinical evidence through early 2025.

professional.heart.org

Alex Chang, MD @alexchangmd.bsky.social · last yr.

2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults 08/28/25 @ 12:00 pm – 1:30 pm CDT Featuring writing committee members and highlights from the ACC/AHA Committee on Clinical Practice Guidelines targetbp.org/event/target...

Target BP: Webinar – Target:BP

targetbp.org

Josh Waitzman @jwaitz.bsky.social · last yr.

A bold guideline from the beginning! “We suggest that all individuals with hypertension be screened for primary aldosteronism”

two cats are standing next to each other with the words " it is bold i like it " above them

ALT: two cats are standing next to each other with the words " it is bold i like it " above them

media.tenor.com

Endocrine Society@endocrinesociety.bsky.social · last yr.

Our latest clinical practice guideline, Primary Aldosteronism (bit.ly/44MbrSv), is now available. The new guideline recommends more widespread screening for a common hormonal cause of high blood pressure known as primary aldosteronism. Read in @endocrinenews.bsky.social: bit.ly/4kFadhv #ENDO2025

Jean Wassenaar, MD PhD @jeanwassenaar.bsky.social · last yr.

Balancing the risk for clotting and bleeding is constant challenge for cardiologists, so I was very excited to see in this month’s #JACCBTS work on targeting different parts of the coagulation cascade (Factor 11, FXI) to reduce bleeding risk while lowering risk for thrombosis. 🧵: 1/8

Wanpen Vongpatanasin @drwanpen.bsky.social · last yr.

New PA Endo guideline is also out by experts @anandvaidya17.bsky.social #Cardiosky @hswapnil.medsky.social doi.org/10.1210/clin...

Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline

AbstractBackground. Primary aldosteronism (PA), a primary adrenal disorder leading to excessive aldosterone production by one or both adrenal glands, is a

doi.org

Heather Gornik @heatherlgornik.bsky.social · last yr.

We have an unexpected late opening in our vascular medicine 1 year fellowship program for 2025-2026 @harringtonhvi.bsky.social Outstanding clinical training with multi specialty faculty in a highly collaborative environment. Chat if interested and please help spread the word. #CardioSky

Michael Raddatz @michaelraddatz.bsky.social · last yr.

In this month’s issue of #JACCBTS, Jønck, et al. explore the effects of cytokine inhibitors on cardiovascular adaptability in rheumatoid arthritis (RA). Read below to see what they found! 🧵 1/9 @jaccjournals.bsky.social

Title page of a paper titled IL-6 inhibitors and TNF inhibitors: Impact on Exercise-induced Cardiac Adaptations in Patients With Rheumatoid Arthritis

Joseph Flynn, MD @jostflynnmd.bsky.social · last yr.

It's World Hypertension Day #nephsky #medsky mailchi.mp/whleague.org...

Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · last yr.

There you have it: BEDMED published in @jama.com jamanetwork.com/journals/jam... h/t @drjmluther.bsky.social No difference in bedtime versus morning BP meds - as expected #NephSky #Hypertension 1/

Figure of survival curve showing no difference

Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · last yr.

Also read the accompanying editorial from @jordybc.bsky.social www.acpjournals.org/doi/10.7326/... Don’t let the complexity of traditional PA screening and confirming diagnosis stop you - just measure renin to start and go from there

Rethinking Confirmatory Testing in Primary Aldosteronism | Annals of Internal Medicine

acpjournals.org

Jean Wassenaar, MD PhD @jeanwassenaar.bsky.social · last yr.

I’ll always remember the first congestive hepatopathy patient I took care of as an intern @vumc.bsky.social. The pathology was so different from anything else, so when I saw an article on this in this month’s #JACCBTS I couldn’t wait to learn more about it. (🧵: 1/10) @jaccjournals.bsky.social

Jean Wassenaar, MD PhD @jeanwassenaar.bsky.social · last yr.

Follow @michaelraddatz.bsky.social @jeffhsumd.bsky.social and @vascularimmuno.bsky.social and I for more updates on great science from #JACCBTS (🧵: 10/10)

Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · last yr.

The ASIs have arrived www.nejm.org/doi/full/10.... Aldosterone synthase inhibitors - first one to finish the phase 3 line #Lorundrostat #Hypertension

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM

Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...

nejm.org

Hypertension Canada @hypertensioncanada.bsky.social · last yr.

Josh Leisring @joshleisring.bsky.social · last yr.

Interesting case report: an unusual (and new to me) etiology of AME. academic.oup.com/jcemcr/artic... #nephsky

An Unusual Cause of Hypokalemia to Consider

Abstract. Apparent mineralocorticoid excess syndrome is a rare disorder that can be acquired through inhibition of the enzyme 11 β-hydroxysteroid dehydroge

academic.oup.com

Heather Gornik @heatherlgornik.bsky.social · last yr.

Great pearls by @jbrianbyrd.bsky.social in evaluating pts for RDN at #ACC25: 1. confirm uncontrolled HTN with out of office measure (Amb BP monitor); 2. trial spironolactone 1st; 3. shared decision making key - care team should include HTN specialists beyond those performing the procedure #cardiosky